Menu
Search
|

Menu

Close
X

Tonix Pharmaceuticals Holding Corp TNXP.OQ (NASDAQ Stock Exchange Global Market)

3.28 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 3.28
Open --
Volume --
3m Avg Volume 14,813
Today’s High --
Today’s Low --
52 Week High 9.38
52 Week Low 2.85
Shares Outstanding (mil) 7.51
Market Capitalization (mil) 36.27
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.694
FY16
-17.355
FY15
-28.635
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.07
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-77.69
14.43
Return on Equity (TTM)
vs sector
-77.82
16.13

EXECUTIVE LEADERSHIP

Seth Lederman
Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $472,500.00
Bonus: --
Bradley Saenger
Chief Financial Officer, Treasurer, Since 2016
Salary: $301,361.00
Bonus: --
Jessica Morris
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Gregory Sullivan
Secretary,Chief Medical Officer, Since 2017
Salary: $335,000.00
Bonus: --
John Rhodes
Lead Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

509 Madison Ave Rm 306
NEW YORK   NY   10022-5583

Phone: +1212.9809155

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

SPONSORED STORIES